Investigation of mechanisms about therapeutic resistance due to the difference of pancreatic stellate cell phenotypes and development of nano capsule including anti-stromal drugs

2015 Fiscal Year Final Research Report

• Project/Area Number: 25462116
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Digestive surgery
• Research Institution: Kyushu University
• Principal Investigator: MAEYAMA Ryo 九州大学, 医学(系)研究科(研究院), 共同研究員 (10611668)
• Co-Investigator(Kenkyū-buntansha): MIZUMOTO Kazuhiro 九州大学, 大学病院, 准教授 (90253418) ; TOMA Hiroki 九州大学, 医学研究院, 共同研究員 (80437780) ; OHUCHIDA Kenoki 九州大学, 大学病院, 助教 (20452708)
• Project Period (FY): 2013-04-01 – 2016-03-31
• Keywords: 膵癌間質細胞 / 膵星細胞 / 抗間質薬

Outline of Final Research Achievements

We analyzed about expression of CD146 and CD51 in pancreatic stellate cells by immunohistochemistry of human pancreatic cancer specimens. Expression of CD146 was negatively related with patients prognosis, whereas expression of CD51 was positively related. In vitro and in vivo experiments showed expression of CD146 in pancreatic stellate cells attenuated aggressiveness of cancer cells, although CD51 enhanced the tumorigenecity. Next we focused on pirfenidone and calpeptine which are known as anti-stromal drugs and their effect of pancreatic cancer tumor growth by Xenograft mouse model. These drugs showed significant reduction of fibrosis in tumor microenvironment via suppression of stellate cells, in addition they enhanced anti-tumoral effect of gemcitabine. These data indicates that targeting specific subgroup of stellate cells by anti-stromal agents could be a promising treatment.

Free Research Field

医歯薬学